CL097, A TLR7/8 Ligand, inhibits TLR-4-dependent activation of IRAK-M and BCL-3 expression

Shock

Volumn 32, Issue 5, 2009, Pages 484-490

  Petricevic, Branka ^a   Wessner, Barbara ^a,b   Sachet, Monika ^a   Vrbanec, Damir ^c   Spittler, Andreas ^a   Bergmann, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c KBC Zagreb   (Croatia)

Author keywords

Bcl 3; Cytokines; Immunosuppression; IRAK M; LPS; TLR

Indexed keywords

ANTINEOPLASTIC AGENT; CL 097; HYALURONIC ACID; IMIDAZOQUINOLINE DERIVATIVE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE M; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; PROTEIN BCL 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BREAST CANCER; BRONCHUS CANCER; CELL CULTURE; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME SYNTHESIS; EX VIVO STUDY; HUMAN; HUMAN CELL; MACROPHAGE; METASTASIS; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SEPSIS;

ADULT; AGED; CELLS, CULTURED; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; HYALURONIC ACID; IMIDAZOLES; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-10; INTERLEUKIN-12; LIGANDS; LIPOPOLYSACCHARIDES; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; QUINOLINES; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350221029     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181a5ac8a     Document Type: Article

References (32)

1. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW: Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:1341-1347, 1995.
2. van Till JW, van Veen SQ, van Ruler O, Lamme B, Gouma DJ, Boermeester MA: The innate immune response to secondary peritonitis. Shock 28:504-517, 2007.
3. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, Redl H, Roth E, Spittler A: Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 25:129-134, 2006.
4. Alomao R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, Mendes ME, Gomes NE, Rigato O: TLR signaling pathway in patients with sepsis. Shock 30:73-77, 2008.
5. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754, 1991.
6. Wiersinga WJ, Van't Veer C, van den Pangaart PS, Dondorp AM, Day NP, Peacock SJ, van der Poll T: Immunosuppression associated with interleukin-1RYassociatedYkinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009 Dec 26. [Epub ahead of print].
7. Van't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, de Vos AF, van der Poll T: Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 179:7110-7120, 2007.
8. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110:191-202, 2002.
9. Lin WJ, Yeh WC: Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 24:206-209, 2005.
10. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA, Standiford TJ: Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 116:2532-2542, 2006.
11. Xie Q, Gan L, Wang J, Wilson I, Li L: Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 44:3453-3461, 2007.
12. del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P, Escoll P, Baos R, Caveda L, Garcia F, et al.: Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinaseYM expression via CD44 and TLR4. J Immunol 174:3032-3040, 2005.
13. Wessells J, Baer M, Young HA, Claudio E, Brown K, Siebenlist V, Johnson PF: BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 279:49995-50003, 2004.
14. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH: Negative regulation of Toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 317:675-678, 2007.
15. Kawai T, Akira S: TLR signaling. Cell Death Differ 13:816Y 825, 2006.
16. Trinchieri G, Sher A: Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7:179-190, 2007.
17. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR: The expression of Tolllike receptors 3 and 7 in rheumatoid arthritis synovium is increased and co-stimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 52:2313-2322, 2005.
18. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A: Selected Tolllike receptor agonist combinations synergistically trigger a T helper type 1Ypolarizing program in dendritic cells. Nat Immunol 6:769-776, 2005.
19. Bekeredjian-Ding I, Roth SI, Gilles S, Giese T, Ablasser A, Hornung V, Endres S, Hartmann G: T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol 176:7438-7446, 2006.
20. Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM: HIV-1 activates macrophages independent of Toll-like receptors. PLoS ONE 3:e3664, 2008.
21. Escoll P, del Fresno C, Garcia L, Valles G, Lendinez MJ, Arnalich F, Lopez-Collazo E: Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 311:465-472, 2003.
22. Bergmann M, Gornikiewicz A, Sautner T, Waldmann E, Weber T, Mittlbock M, Roth E, Fugger R: Attenuation of catecholamine-induced immunosuppres-sion in whole blood from patients with sepsis. Shock 12:421-427, 1999.
23. Miller RL, Meng TC, Tomai MA: The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21:69-87, 2008.
24. Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I, Wieckiewicz J, Zembala M: Tumor cellYinduced deactivation of human monocytes. J Leukoc Biol 74:1094-1101, 2003.
25. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J: MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178:1164-1171, 2007.
26. Morris GE, Parker LC, Ward JR, Jones EC, Whyte MK, Brightling CE, Bradding P, Dower SK, Sabroe I: Cooperative molecular and cellular networks regulate Toll-like receptorYdependent inflammatory responses. FASEB J 20: 2153-2155, 2006.
27. Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P: The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J 21:1575-1585, 2007.
28. Bergmann M, Sautner T: Immunomodulatory effects of vasoactive catechol-amines. Wien Klin Wochenschr 114:752-761, 2002.
29. Liew FY, Xu D, Brint EK, O'Neill LA: Negative regulation of Toll-like receptorYmediated immune responses. Nat Rev Immunol 5:446-458, 2005.
30. Liu ZJ, Yan LN, Li XH, Xu FL, Chen XF, You HB, Gong JP: Up-regulation of IRAK-M is essential for endotoxin tolerance induced by a low dose of lipopolysaccharide in Kupffer cells. J Surg Res 150:34-39, 2008.
31. Marchant A, Deviere J, Byl B, De Groote D, Vincent JL, Goldman M: Interleukin-10 production during septicaemia. Lancet 343:707-708, 1994.
32. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H: Role of Toll-like receptors in the development of sepsis. Shock 29:315-321, 2008.